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ABSTRACT 
 
NONLINEAR STIFFNESS AND VISCOELASTICITY OF INHIBITOR-TREATED 
BLOOD CLOTS BY TENSILE TESTING 
 
by Wilson S. Eng 
 
Although blood clots are vital to wound healing, little is known about what factors 
influence clot stiffness and dynamic response. This work investigates the mechanics of 
inhibitor-treated clots by direct tensile testing using a custom designed system for forces 
below 1 N. Inhibitors that affect clot formation include blebbistatin, which affects myosin 
II movement on actin, and cytochalasin D, which affects actin polymerization. The 
hypothesis of this investigation is that blebbistatin will have a greater effect on 
mechanical behavior than cytochalasin D, because the inhibition of myosin II will 
weaken the overall clot more than actin. This hypothesis was investigated using clots that 
were treated with blebbistatin and cytochalasin, using untreated whole blood as a 
reference. Clots were tested from five different donors with at least two replicates from 
each donor. Each clot was subjected to an initial stretch ratio of 1.5 to measure nonlinear 
stiffness, followed by a series of 1 mm increments to record stress relaxation. At a stretch 
ratio of 1.5, blebbistatin-treated clots exhibited 4.3% lower tensile stress than 
cytochalasin-treated clots. The relaxation time constant for blebbistatin-treated clots was 
10% faster than for cytochalasin-treated clots. This evidence supports the hypothesis 
about the role of myosin II in blood and introduces experimental methodology that can be 
extended to studies on mechanics of other soft biological tissues. 
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1. INTRODUCTION 
 
1.1 Background 
 
Blood clots are critical to preventing incessant bleeding, thus saving lives. The 
mechanical properties of the clot are vital to damming blood flow. The macroscopic 
mechanical properties of a blood clot such as stress-strain response and yield strength are 
functions of the blood composition and extent of cross-linking. Cross-linking is affected 
by numerous factors, including levels of a coagulation enzyme known as factor XIII 
(FXIII). However, several studies over the past few years have shown that blood clots are 
mechanically and morphologically heterogeneous in microscale, and micromechanical 
behavior can have important consequences in pathophysiological events such as stroke 
[1].  
Clots are biocomposite materials that are formed as liquid blood transforms into a 
viscoelastic state. Fibrin, a key structural component of blood, is a polymer chain that has 
been shown to shift from a random orientation to an aligned configuration when strained 
[2]. The unique restructuring trait allows the clot to be flexible, but also resilient to 
external forces [3]. However, mechanical testing of a clot is not a simple task. The fluid-
like consistency of blood makes mechanical property testing with conventional 
macroscale instruments such as an Instron® universal testing system (Illinois Tool Works, 
Norwood Massachusetts, USA) difficult in terms of fixturing and small-force resolution. 
Krasokha et al. found that casting blood into a mold was helpful in compressive testing 
because of the known dimensions and cross-section [4]. However, even with a well-
prescribed shape, the blood consistency is difficult for an experimental device to grasp, 
2 
 
requiring unconventional mounting techniques to contain the specimen within the 
apparatus. In order to perform more informative mechanical testing of blood clots, there 
is a need for a versatile and sensitive apparatus that can apply finely controlled 
tensometric (i.e., force measurement under prescribed displacement) or extensometric 
(i.e., displacement measurement under applied force) testing in a consistent way.  
1.1.1 Blood Clotting Mechanics 
Blood clots are complex and have many clotting factors and pathways that can create 
 D  F O R W   9 L U F K R Z ¶ V  W U L D G   Q D P H G  D I W H U  5 X G R O I  9 L U F K R Z   G H V F U L E H V  W K H  W K U H H  F R Q W U L E X W L Q J 
causes to thrombosis which are stasis, vessel wall injury, and hypercoagulability [5]. 
Fluid flow plays a role in the formation of clots. For example, a higher concentration of 
platelets tends to occur in arterial clots, for which fluid flow tends to have a higher flow 
rate than in veins [6]. The first stage of clotting occurs when there is an open wound. 
Vasoconstriction of endothelial cells occurs, because of a lack of nitric oxide for 
vasodilation during injury. In the second stage, platelets gather to form a plug at the 
wound, but will not be cross-linked until after coagulation occurs to prevent further 
bleeding with a stronger clot [7]. In the coagulation cascade there are two pathways, 
known as the intrinsic pathway and extrinsic pathway. The intrinsic pathway is a slower 
process using collagen and requires contributing roles of factors FXII, FXI, FIX, and FX. 
The extrinsic pathway is a faster process requiring only FVII, tissue factor (TF), and FX. 
The intrinsic pathway and extrinsic pathway meet at FX to start the common pathway. 
The blood stream contains enzymes that change prothrombin (FII) into thrombin via 
factor Xa (where the letter "a" indicates activator). Activated platelets are able to 
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rearrange their structure to attach to fibrinogen (FI) on neighboring platelets to create a 
stronger plug at the injured site [8]. Eventually a network of platelets is created and its 
strength is enhanced when thrombin converts the fibrinogen into a fibrin a mesh that 
helps prevent blood flow. The fibrin network is then strengthened with the introduction of 
FXIII, which cross-links the structure allowing for greater strain stiffening and 
viscoelastic stiffness of blood clots [9].  
This study will focus on the common pathway, for which collagen and tissue factor 
are not involved with initiating the clotting process. Thrombin is the enzyme used to 
initiate the clotting process, after which the clot will form and contract over time. Two 
platelet components that provide hemostatic clot structure by working together are actin 
filaments and myosin II motor proteins [10]    7 K H  S O D W H O H W ¶ V  O R F D O  D F W L Q-myosin 
cytoskeleton relationship will be investigated further with the use of blebbistatin as a 
known drug that inhibits myosin II [11] and cytochalasin D as a known drug that inhibits 
actin polymerization [12]. Blebbistatin was found to change the biconcavity shape of red 
blood cells (RBC) due to the inhibition of myosin II, indicating structural weakening 
[13], whereas cytochalasin D was found to also weaken the clots by capping actin 
filaments as shown through thromboelastography (TEG) which is a test for blood 
coagulation efficiency [14]. 
1.1.2 Mechanical Properties of Blood 
Many engineering materials such as metals exhibit linearly elastic mechanical 
 E H K D Y L R U  W K D W  I R O O R Z  + R R N H ¶ V  O D Z   I R U  Zhich displacement is proportional to force. 
However, blood clots behave differently, since the cross-linked fibrin network is strain 
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stiffening. The structural rearrangement of fibers results in tension that is not linearly 
proportional to the applied displacement. Hyperelastic models, such as Neo-Hookean 
model or Mooney-Rivlin model, are methods to describe the strain stiffening 
characteristic. 
There is also a difference when a clot is held at a prescribed displacement, because 
stress relaxation will occur. Linearly elastic materials will exhibit a constant force when 
extended and held at a fixed strain below the yield strain of the material. In the stress 
relaxation of blood clots, however, tension decreases with time when the clot is held at a 
fixed displacement. Viscoelastic models are used to describe this stress relaxation 
phenomenon with the use of springs and dampers in various configurations. The most 
basic models are the Maxwell model, consisting of a spring and damper in series, and the 
Kelvin-Voigt model, consisting of a spring and damper in parallel. The Maxwell model is 
better for stress relaxation for which displacement is fixed and the mechanical elements 
encounter reduced force, and the Kelvin-Voigt model is better for creep for which force 
is fixed and the mechanical elements undergo changes in geometry. The work in this 
thesis will use the standard linear solid model, which is also known as a Zener or a 
Maxwell representation that combines the Maxwell model and Kelvin-Voigt model [15]. 
1.2 Hypothesis  
The work in this thesis investigates nonlinear stiffness and viscoelastic response of 
blood clots by performing mechanical tensile testing of clots subjected to inhibitors. The 
hypothesis is that blebbistatin affects stiffness and viscoelastic response of a clot more 
5 
 
than cytochalasin D, because myosin II plays a larger role than actin in clot stiffness. 
Inhibition of myosin II with blebbistatin is expected to create a weaker clot.  
Myosin II protein is composed of two intertwined myosin chains which act along 
actin filaments through an adenosine triphosphate (ATP) energy cycle. ATP binds to a 
myosin II that begins to release the attached actin. The ATP is converted to adenosine 
diphosphate (ADP), a phosphate and energy which winds the myosin like a spring to 
provide mechanical energy. When the phosphate is released from myosin, the stored 
energy from the myosin is released to move along the actin filament, thus contracting. 
Blebbistatin can cause the myosin II to have low affinity to attach to actin, disrupting the 
phosphate activation site, by binding to ATPase intermediate with ADP [16]. If the actin 
filament is capped with cytochalasin D, then the contractions from the myosin will be 
shorter. However, if there is no myosin II activity, then the membrane proteins will be 
unable to contract and can be easily deformed [17]. 
1.3 Significance 
There is still much unknown about the mechanical properties of blood clots. 
Understanding the mechanical properties of blood clots is important because of the 
potentially informative benefit to medical interventions such as drug therapy or 
thrombectomy. Most prior work in mechanical characterization of blood clots has been 
done using either rheometry, which measures tangential stress on a surface, or at the 
nanoscale with atomic force microscopy (AFM), which focuses on individual clot 
components. Direct tensile testing as applied in this thesis will provide an under-
investigated methodology for characterizing blood clot mechanics.  
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2. RELATED WORK 
2.1 Mechanical Properties of Fibrin and Other Biomaterials 
When fibrinogen and thrombin are combined, a fibrin polymer is formed. Fibrin is an 
important structural component of blood clots that plays a role in treating ischemic 
strokes and myocardial infarctions, but a balance is needed because too much fibrin can 
lead to thrombosis and too little allows for uncontrollable bleeding [18]. Fibrin plays a 
versatile role in wound healing and angiogenesis [19]. A specific use of fibrin is fibrin 
sealant which is used in surgery as a hemostatic agent, preventing blood loss [20].  Fibrin 
has viscoelastic properties which are important in understanding and treating thrombosis. 
Fine clots are simpler to measure, because the planarity creates a two dimensional 
interaction rather than a three dimensional interaction that is more complicated [21]. A 
strong clot will deform differently than a weak one due to the nonuniform strain 
stiffening network. Biological tissues and clots benefit from strain stiffening, which 
allows for larger deformations prior to rupture [22]. A fibrin network can be cross-linked 
with FXIII to create a stronger clot. Due to its versatility of strength and biocompatibility, 
fibrin is already used in biomedical implants and tissue engineering [18].  
Hydrogels are biomaterials consisting of water insoluble polymer chains with cross-
linking properties [23]. Alginate is an example of a hydrogel material that exhibits 
mechanical behavior similar to the mechanical behavior of fibrin. Sodium alginate, a 
seaweed and kelp extract, has biocompatible characteristics that are favorable for wound 
healing and drug delivery systems. Alginate increases angiogenesis which helps facilitate 
the development of new blood cells increasingly for seven days [24]. Similar to fibrin, 
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alginate can be cross-linked ionically, thermally, covalently, and through cellular 
adhesion [25]. Drury et al. found that alginate ionically cross-linked with sodium chloride 
had stress-strain curves with an initial concavity upward for the strain stiffening portions 
of the plot [26]. When ionically cross-linked, alginate exhibits nonlinear stiffness similar 
to blood clots. A few other hydrogels such as heparin, chitosan, and agarose are also used 
in tissue engineering for their biocompatibility, biodegradability, and strain stiffening 
mechanical characteristics [23].  
2.2 Methods for Mechanical Testing of Soft Materials 
Soft biomaterials are typically small and difficult to handle. The consistency is 
similar to a gel, which can lead to slippage when trying to grasp mechanically. However, 
certain measurement techniques alleviate this issue of slippage. The test methodologies 
vary between apparatus types to bypass the specimen consistency. Rheometry uses the 
specimen soft gel consistency to measure material properties. Chemical adhesion holds 
the specimen in place and allows atomic force microscopy (AFM) to be used. A cast 
specimen allows for compression or tension testing. Electrowetting uses an electric field 
to manipulate the specimen into the desired configuration. The reviewed testing methods 
provide guidance on developed techniques to overcome slippage from grasping soft 
biomaterials.  
2.2.1 Rheometry 
A rheometer is a mechanical testing device that uses a rotating cone to compress the 
specimen in a medium at a prescribed rotational speed, thus providing mechanical 
characterization based on shear rate. Kim et al. studied fibrin, collagen, and fibrin-
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collagen with a rheometer that compressed the specimens to 1/10 of the initial thckness 
to gather shear modulus information [27]    7 K H  V K H D U  H O D V W L F  P R G X O X V  * ¶  D Q G  V K H D U  O R V V 
 P R G X O X V  * ·  D U H  W K H  W \ S L F D O  S U R S H U W L H V  W K D W  D U H  U H S R U W H G  I U R P  U K H R P H W U \  P H D V X U H P H Q W V  
Wen et al. [22]  I R X Q G  W K D W  D Q  R X W  R I  S K D V H  Y L V F R X V  U H V S R Q V H  R I  * ¶ ¶ L V  O H V V  W K D Q  * ¶  L Q  F U R V V-
linked hydrogels, because nonlinear elasticity has a nonlinear stress and strain 
relationship. Polyacrylamide (PA) gels, for example    K D Y H  * ¶  L Q F U H D V H  Z L W K  O D U J H U  V W U D L Q V  
indicating that strain stiffening is occurring   * ¶  D Q G  * ·  D U H  S U R S R U W L R Q D O  W R  W K H  V W R U H G 
elastic energy and the energy dissipated [28]. 
Ayala et al. studied the effects of cytochalasin D and blebbistatin on blood with 
rheometry [29]. A dosage dependency between 2.5 µM to 5.0 µM cytochalasin D and 5.0 
µM to 10 µM blebbistatin was found, because the shear modulus continued to change 
[29]. If the shear modulus was steady, then the entire clot structure was inhibited. 
Tutwiler et al. tested whole blood by keeping the clot size at a constant volume with the 
rheometer and found that the increase in red blood cells weakens the clot contractile 
stress [30]. Rheometry methods proved to be useful in studying blood clots and inhibitor 
effects, but would not be able to measure actual tensile forces acting on soft biological 
materials. 
2.2.2 Atomic Force Microscopy 
In nanoscale, Markert et al. used AFM to test several biomaterials including alginate, 
collagen, and fibrin [31]. With AFM devices, a measured force can manipulate the 
specimen and image simultaneously. Studies by Feller showed that an AFM probe tip can 
adhere to blood and provide nanonewton force measurements with micron-scale 
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displacements by partially submerging the cantilever beam [32]. The nanometer scale 
allows for studying the mechanical properties of single components of a clot. Other 
methodologies can prepare the specimen for AFM such as electrospinning, which allows 
for a thinner fiber to be created [33]. However, larger networks in the macro scale are 
difficult to understand, because of the very fine resolution of AFM devices.  
 Examining a whole clot at macroscale, Lam et al. investigated the mechanics and 
dynamics of platelets with force measurements [34]. Crow et al. further introduced 
cytochalasin D and blebbistatin to understand the inhibitors effects on clot retraction [35]. 
When treated with a cytochalasin D concentration of 500 nM, clots contracted at 0.40 
µm/min. When treated with a blebbistatin concentration of 30 µM, clots contracted at 
0.24 µm/min. Clot contraction ceased while using 1 µM cytochalasin and 50 µM 
blebbistatin concentrations [35].  
2.2.3 Compression Testing 
Compression testing is another test methodology performed on biomaterials. 
Typically the test specimen will be in a holder and compressed to obtain relevant 
mechanical properties. This system benefits from the not having to grasp onto the soft 
biomaterial. Krasoskha et al. tested porcine blood by compression at 0.25 mm/s by a plate 
in a chamber where the clot takes the chamber shape [4]. Beyond 70% compression a 
strain stiffening effect was observed with a large increase in stress [4]. However, the 
methodology did not have a specified predetermined clot shape and chamber walls could 
have affected the results. There was no indication of a retraction period for the clot, such 
that the observations could have been more related to plasma rather than the actual clot. 
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In contrast with Murphy et al. who performed compression testing on round fibrin gel 
specimens between two plates on an Instron® universal testing machine [36]. The 
compression of the fibrin gel did not have any interference, because the gel was able to 
retain its own structure. The compression testing proved to be a simple way of testing 
clots, but tensile testing is more indicative of clots breaking apart in embolisms. 
2.2.4 Tensile Testing 
Flexures have been used to measure contraction and small movements in tensile 
testing. Known flexural stiffness allows for simple forces measurements with a known 
displacement. Polydimethylsiloxane (PDMS) strain sensing beams were used to measure 
clotting contraction forces with the You  Q J ¶ V  P R G X O X V  R I  W K H  I O H [ X U H  D Q G  G L V S O D F H P H Q W 
[37]. The same principles were used for flexures to study the strength of an onion skin in 
dry and wet conditions [38]. A similar experiment by Kim et al. [39] was done using a 
piezoelectric actuator and a flexure as the known force, a variation of the approach by 
Zamil et al. [38]. The flexure stiffness was known, allowing the onion movement to be 
measured. 
 Currently, there is no current standard for tensile testing soft biological materials 
such as hydrogels and fibrin. There are commercial products that can test soft biological 
tissue, such as the DMT wire myograph (Danish Myo Technology, Aarhus, Denmark). 
However, the device is specialized for loop arteries that attach to the two wires and are 
pulled apart. ADMET has a BioTense Bioreactor (ADMET, Norwood Massachusetts, 
USA) that measure forces between 1 mN to 5 N at 1.2 mm/s, but does not have a quick 
clamping system for soft biological materials. Other industrial testers such as an Instron® 
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universal testing machine can be used, but a large specimen must be made to obtain 
readings. Thrombin added to fibrinogen and cross-linked with FXIII were used in a 
casting of 4 mm diameter x 60 mm long, and the measured forces were as high as 0.8 N 
with an extension of two times the normal length [2]. Soft biological materials may not 
always be large, so a smaller specimen scale solution is necessary. 
Some tensile testers are created for very specific tests. Jacquet et al. created an 
extensometer to test the mechanical properties of skin on human subjects [40]. The 
device used a linear variable displacement transducer (LVDT) and strain gauges to 
measure skin displacement. Krone et al. bonded a hydrogel to silicon, allowing clamps to 
directly hold the composite specimen to be pulled apart with a Futek load cell [41]. 
Krasokha et al. casted porcine blood in an aluminum mold, and then aged the clots for 48 
hours to be pulled apart horizontally with their tensile tester [4]. However, the data drawn 
from the tensile testing did not comprise of a continuous data set and had two distinct 
different linear slopes in the stress vs. elongation plots. A contributing factor may have 
been that aged clots were more brittle. Tensile testing proved to be possible on blood 
clots, but the data were not as refined as other methods such as AFM or rheometry, 
possibly due to the difficulty of pulling on blood clots.  
2.2.5 Electrowetting-On-Dielectric 
Electrowetting-on-dielectric (EWOD) is a principle in digital microfluidic devices 
that uses electrostatic forces to move a liquid on a specialized hydrophobic platform. The 
platform has a set of activation pads that turn a voltage on and off to move the fluid 
around the device [42], [43]. EWOD platforms can be used to test clots, since the device 
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can activate separate pads to pull the specimen apart or move to the desired location. The 
device is has fine enough resolution to create 900 nL cross-linked alginate specimen on 
the platform [44]. The placement of calcium chloride relative to the sodium alginate is 
important, because irregular shaped gels can be formed due to the cross-linking reaction 
time. A uniform gel was created by moving the calcium to the alginate, so the excess 
liquid could easily be removed after gel formation [44]. The EWOD platform is 
promising as an emerging technology, but the blood viscosity and clot strength may be 
difficult to overcome.  
2.3 Specimen Holding Methods  
Holding methods vary from apparatus to apparatus as indicated earlier. The main 
methodologies are through compression, clamping, and special adhesion coatings. 
Rheometry does not require special holding methods, because the volume is controlled by 
the rotating compression disk. Krashoka et al. relied on the chamber dimensions and plate 
to keep the specimen in place [4]. Murphy et al. was able to cast samples into a 
prescribed shape when platens were used to compress the specimen [36]. 
A variety of methods and test shapes have been used for tensile testing. Typically all 
of the hardware used for holding clots or clot-like specimens are simplistic flat clamps 
with screws to adjust the clamping force. The clamping methodology is possible if the 
specimen is large and structurally strong enough to withstand outside forces. Brown et al. 
created a specimen that was 4 mm diameter cylinder x 60 mm long cast of fibrinogen, 
thrombin, and FXIII mixture [2]. The specimen retained its shape and was held together 
with a rubber clamp for tensile testing. Krone et al. had a different approach by using a 
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thin film bonded with a hydrogel, using a bonded bi-layer to characterize the mechanical 
response via strain energy functions [41]. The method factored out the contributing 
mechanical role of silicon to obtain the mechanical properties of only the hydrogel.  
Chemical adhesion techniques have also been used to secure a specimen on to glass 
slides for pull testing. In order to promote adhesion of fibrin to glass substrates, surfaces 
were pretreated with fibrinogen as in [45]. Fibrin can also attach to glass sides via poly-l-
lysine (PLL) coating mixed with fibrinogen, which has a net negative charge at pH 7.4 
allowing for a bond based on polarity [46]. Adhikari et al. used a peripheral venous 
catheter tube to create fibrin specimens in 0.8 mm x 5 cm which were able to retain the 
shape even after being removed with a syringe to be placed on glass slides using 
cyanoacrylate adhesive [18]. A collagen adhesion method uses collagen directly on 
slides, allowing time for gelling to promote adhesion [47]. Alginate can adhere to slides 
with PLL and then barium chloride, under which conditions the PLL, will bind to the 
prostate-specific membrane antigen on one side and alginate will adhere to the other side 
[47].  
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3. THEORY 
Three applications of mechanical engineering theory are presented in this chapter: (1) 
stiffness compensation for inline sensing, (2) nonlinear material stiffness, and (3) lumped 
parameter modeling of viscoelasticity. 
3.1 Stiffness Compensation for Sensing 
The ability of a cantilever-type load cell to measure small forces is partially attributed 
 W R  W K H  O R D G  F H O O ¶ V  U H O D W L Y H O \  O D U J H  F R P S O L D Q F H   F R P S D U H G  W R  D  E X W W R Q  R U  V-beam load cell, 
for example). Placing the load cell in series is advantageous because the load cell cannot 
be overloaded. Once the specimen tears, the actuator is no longer coupled to the load cell. 
As the actuator applies displacement, however, the mechanical response of the system 
as measured by the load cell includes a mechanical response of the test specimen as well 
as the stiffness of the load cell body. Figure 1 illustrates the mechanical coupling 
arrangement. 
 
Figure 1. Mechanical coupling from actuator through specimen to load cell, as arranged 
spatially (a) and as equivalent stiffness elements (b). 
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Thus, in order to isolate specimen mechanics, both the displacement and the stiffness 
contributions must be decoupled. The elongation / s of the specimen is the displacement 
/ total of the actuator minus the tip deflection / L of the load cell. The tip deflection of the 
load cell can be measured in real time under a microscope or characterized prior to 
experimentation based on the measured stiffness kL (i.e., by applying a known load, 
measuring tip deflection, and fitting a line to the slope). The stiffness of the load cell can 
also be estimated by a cantilever beam equation using Young's modulus (if known) and 
geometric dimensions, although measurement using known weights is more direct and 
accurate. 
When considering only the instantaneous stiffness of the specimen (i.e., not 
including viscous effects), the load cell stiffness kL and the specimen stiffness ks have an 
equivalent stiffness keq as shown in equation (1). 
 
 
(1) 
 
In quasi-static tensile testing, the force F throughout the series assembly is constant, 
and the ratio of measured force to actuator total displacement provides the equivalent 
stiffness, such that the measured force and applied displacement are related to specimen 
stiffness as shown in equation (2). 
 
 
(2) 
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Rearranging equation (2) provides an expression for the specimen stiffness in terms 
of the measured force, applied displacement, and (separately characterized) load cell 
stiffness, as shown in equation (3). 
 
 
(3) 
 
 
3.2 Nonlinear Material Stiffness 
Broad categories of material models include linear elastic, nonlinear elastic 
(hyperelastic, for example), and viscoelastic, all of which can be characterized by 
uniaxial testing. For mechanical testing, linear elastic materials are conventionally 
characterized solely by tensile or compressive Young's modulus E. Poisson's ratio   is 
also an important linear elastic parameter, but for small test specimens the value is not 
typically measured and reported. 
Three common ways of describing geometric change for uniaxial tensile test 
specimens are elongation / , axial strain 0, and stretch ratio  . Elongation / , of a loaded 
specimen is defined as difference between the specimen length L (in its loaded state) and 
its original length Lo. Axial strain 0 is the component of displacement gradient along the 
axial direction, and for discrete measurements can be expressed as the ratio of elongation 
to original length. Stretch ratio   is commonly used in strain energy functions for 
hyperelastic material models, and is defined as the ratio of the specimen length L when 
loaded and its original length Lo when not subject to a load. In this study, Cauchy stress, 
also known as true stress, will be reported in this thesis. Cauchy stress differs from 
engineering stress (which assumes a constant area) by accounting for the change in the 
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specimen cross- ectional area throughout the pull testing. Cauchy stress is more 
completely described as a tensor 1, but for uniaxial tension only the normal component 
111 along the direction of stretch is considered (for which the "11" subscript will 
subsequently be omitted). 
A convenient way to evaluate the strain stiffening properties of the blood clot is with 
a hyperelastic model. Even though blood is a biological material, blood still exhibits 
elastic qualities because the material will retract when released after extension. Although 
complex materials are strain-rate dependent, many soft tissues are known to be 
"pseudoelastic" (i.e., relatively independent of strain rate) [48] and strain-rate sensitivity 
is not examined in this thesis. There are several hyperelastic material models that have 
been investigated for soft tissue biomechanics. Neo-Hookean and Mooney-Rivlin models 
are typically used to describe rubbers, but blood clots have similar elastic deformation 
properties [49], [50]. Constitutive models are based on strain energy density functions, 
for which a set of constitutive parameters are typically fit to experimental data under 
specified loading conditions (e.g., uniaxial, biaxial, or shear) in order to quantify material 
behavior [51]. Equation 4 will be used as a two-parameter Mooney-Rivlin model [50] to 
create a responsive fit for blood clots in this study, and the hyperelastic parameters C1 
and C2 will be extracted from experimental data. However, the Mooney-Rivlin model 
will not have an accurate viscoelastic model with only uniaxial testing, because pure 
shear and equibiaxial testing are needed for a complete viscoelastic model [52]. 
 
(4) 
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3.3 Lumped Parameter Modeling of Viscoelasticity 
Connective tissues have been shown to exhibit both linear elastic and viscoelastic 
behavior under tension [53]. The Maxwell model is comprised of one spring and one 
damper in series and is useful for describing stress relaxation under a prescribed 
displacement. The Kelvin-Voigt model is comprised of one spring and one damper in 
parallel, and is useful for describing creep under a prescribed load. A three-parameter 
viscoelastic model commonly known as a "standard linear model" (occasionally referred 
to as a Kelvin body [54] or a Zener model [15]) uses a spring and damper in series 
arranged in parallel with another spring. This model captures both stress relaxation and 
creep phenomena that the Maxwell and Kelvin-Voigt model represent independently. An 
expanded version of the standard linear model is known as the generalized Maxwell 
model, which is a standard linear model in parallel with many Maxwell models which 
allows for more control in the model. van Kempen performed a rheological test on clots 
with different platelet concentrations contracting on fibrin networks and used a modified 
generalized Maxwell approximation to extract time-dependent, nonlinear viscoelastic 
properties to verify against other rheological approaches [55]. Schmitt et al. characterized 
animal blood by utilizing several models  – Maxwell, Kelvin-Voigt, Jeffrey, Zener, and 
generalized Maxwell. The most appealing of the models is the Zener model, which is 
comprised of both the Maxwell and Kelvin-Voigt models, by being able to predict stress 
relaxation along with creep. Schmitt et al. found that more parameters, such as the 
generalized Maxwell, did not guarantee a better fit when characterizing blood clot 
dynamics [15].  
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The lumped parameter used in this thesis is shown in Figure 2, consisting of a three-
parameter model with two springs and one damper, assembled in series with an additional 
spring element to account for stiffness of the load cell. This configuration was chosen 
because the load cell displacement is not trivial and would contribute to smaller k1, k2, 
and   parameters by approximately 10%. Compensation for the load cell stiffness thus 
provides a more accurate representation of specimen stiffness. 
 
Figure 2. Lumped parameter model, with k2 as a spring in parallel to spring k1, and 
damper      in series added to loadcell kL. 
 
The differential equation for the standard linear model (without kL in Figure 2) is 
shown in equation 5, where F is time-varying force and / s is the elongation of the tested 
specimen. 
 
(5) 
 
In the case of stress relaxation, the imposed elongation remains constant such that its time 
derivative is zero for time t > 0.  Substituting a time constant 2 =  /k1 leads to the 
differential equation in a single variable F(t).  
 
(6) 
 
The Laplace transform with parameter s results in equation 7. 
 
 
(7) 
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Solving this differential equation with initial condition of F(0) = k1/ s+ k2/ s results in 
equation 8 as the solution for elongation in the specimen as a function of time. 
 
 
(8) 
 
The force is then decoupled on the left in equation 9 to perform an inverse Laplace 
transform. 
 
 
(9) 
 
After the inverse Laplace transform, equation 10 presents the force-time relationship for 
the standard linear model without the load cell. 
 (10) 
 
Adding a load cell in series with the standard linear model results in equation 11, where 
the total observed displacement / total accounts for elongation of the specimen as well as 
deflection of the cantilever load cell. Larger forces and a faster displacement will be seen 
in the stress relaxation portion of the experiment, thus the load cell spring stiffness is 
included in the equation. 
 
(11) 
 
Equation 11 will be the equation used to fit a curve to the experimental data. 
MATLAB (The MathWorks, Inc., Natick, Massachusetts, USA) has a nonlinear least 
squares fit function that uses the three variable inputs k1, k2, and  . The function 
minimizes the residual errors between the data sets and requires an initial guess. Both of 
the MATLAB Newton step-based solvers "trust-region reflective" and "Levenberg-
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Marquardt", yielded the same C1 and C2 parameter values in the Mooney-Rivlin equation 
seen in equation 4. 
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4. METHODOLOGY 
4.1 Device Design 
The apparatus for tensile testing consists of a motorized nanopositioner (MP-285, 
Sutter Instrument, Novato, CA), a full-bridge thin cantilever load cell (LCL Series, 
OMEGA Engineering, Norwalk, CT), and a data acquisition (DAQ) signal conditioner 
DI-1000U (Loadstar Sensors, Fremont, CA). The specimen is placed between the 
actuator and load cell using magnetic clamps, as shown in Figure 3.  
 
Figure 3. Major component of tensometer system. 
 
The nanopositioner has 25 mm range with fine resolution of 40 nm per step. Speeds 
are selectable from 20 µm/s to 2.9 mm/s. The data reported in this paper was recorded 
using the 113 g capacity load cell from the LCL product series, but load cells are 
interchangeable with higher-load products of the same family (e.g., 227 g, 454 g, 816 g). 
The DI-1000U DAQ has 24-bit resolution (over 16 million levels) and up to 80 Hz 
sampling rate.  
The test specimen is mechanically in series with the load cell, offering a fail-safe 
design such that the specimen would always tear before the actuator can deflect the load 
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cell beyond its designed range of operation. However, this series arrangement requires 
that the tip deflection of the load cell be subtracted from the raw displacement of the 
actuator, in order to determine the net elongation of the test specimen. 
4.1.1 Functional Requirements 
Mechanical properties of biomaterials are difficult to characterize experimentally 
because many relevant biomaterials such as hydrogel, collagen, and fibrin are pliable and 
viscoelastic. Furthermore, test specimens for substances such as blood clots tend to be 
small in size (i.e., on the order of a few millimeters), requiring fine-resolution positioning 
(i.e., submicron) and sensitive force measurement. Mechanobiological studies further 
require high frequency data recording (i.e., faster than 10 Hz), preferably under 
simultaneous microscope imaging, in order to monitor events such as structural 
remodeling or localized rupture while strain is being applied. A low-profile tensile tester 
that applies prescribed displacement up to several millimeters and measures forces with 
resolution on the order of millinewtons has been designed and tested. 
4.1.2 Specimen Clamping Method 
 
Clamping has been the most successful methodology for pulling soft biomaterial test 
specimens with tensile testing. An aluminum clamp with a toothed crevice as seen in 
Figure 4 allows for two points of contact to hold the test specimen. A magnet was press 
fitted inside the clamp bottom to create a clamping force with the top clamp that has a 
steel screw attached. The magnetic clamping force can be readjusted by turning the screw 
to the desired height and locking the screw in place with the appropriate nut. An 
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adjustable force allows for the clamps to compensate for different sized specimens and 
unwanted damage to the specimens.  
 
Figure 4. Adjustable magnetic clamps used to hold the specimen.  
4.1.3 Displacement Measurement 
The load cell was calibrated using three known weights of 10.950 g, 20.947 g, and 
51.248 g, as measured by a precision balance (Sartorius Research, Gottingen, Germany). 
By adjusting the mN/mV calibration factor, the calibration error was limited to 1% for 
loads up to 508 mN. The rated capacity of the load cell was 1.1 N, which is well above 
the specimens maximum tested force of 300 mN. 
Stiffness of the load cell was determined by applying known weights and measuring 
the corresponding cantilever displacement with an optical comparator (HB400, Starrett, 
Athol, MA). The comparator has a resolution of 2.5 µm at 10X magnification. The load 
cell was placed horizontally in the comparator and a clamp was used to hold the base 
stationary. Calibration weights of 10.950 g, 20.947 g, and 51.248 g were applied and the 
corresponding tip deflection was measured using the optical comparator. As shown by 
the force vs. displacement data in Figure 5, the cantilever load cell had a stiffness of kL = 
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96.883 N/m. The corresponding R² value of 0.9985 with respect to straight-line fit 
indicates a highly linear behavior of the cantilever. 
 
Figure 5. Cantilever load cell stiffness. 
 
Figure 6 shows a representative plot of the zero-load offset and noise of the load cell. 
The signal standard deviation over a 300 s period was 48 µN. The plot shows a mean 
offset of 50 µN and a root mean square (RMS) variation of 68 µN. Typical specimen 
tests are on the order of 100 mN, such that the signal-to-noise ratio is very high. These 
measurements are consistent with manufacturer rating of ± 0.02% accuracy. 
 
Figure 6. Zero-load offset and noise for the load cell. 
 
Zero-load return behavior of the load cell was inspected by repeatedly applying and 
releasing manual load up to 200 mN by pushing with a mechanical micromanipulator. 
The load cell returned to zero (within the previously determined mean offset of 50 µN) 
after each cycle, as evidenced in Figure 7. 
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Figure 7. Zero-load return upon applying and releasing manual loading cycles. 
 
4.2 Experimentation 
 
4.2.1 Experimental Design 
 
Test were conducted at room temperature. The blood draw was compliant with the 
approved F16134 San Jose States Institutional Review Board (IRB) protocol. Five 
different donors were used for the test. Calcium is removed during the blood draw to 
prevent unwanted clotting from initiating and is accordingly reintroduced before pull 
tests to restore the blood to its more natural composition. Four different treatments were 
tested with whole blood as the control, blebbistatin for the myosin II inhibitor, 
cytochalasin D for the actin inhibitor, and the combination of blebbistatin plus 
cytochalasin for observation of combined effect.  
The human blood specimens were fabricated and tested within a 4 hour period after 
the blood was drawn for each treatment. Four specimens were made in each well on a 
chamber slide (Nunc Lab-Tek, Thermo Scientific, Waltham, MA). The tests were 
conducted with two or three successful pulls for each treatment. The order of testing and 
fabrication was whole blood, blebbistatin, blebbistatin plus cytochalasin, and then 
cytochalasin. Between each treatment there was a 30 minute time window to test each set 
of four specimens to complete all of the testing within 4 hours of the blood draw. The 
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whole blood was created first, the blebbistatin incubation mix was started immediately 
after, the blebbistatin plus cytochalasin mix started 30 minutes after the blebbistatin, and 
finally the cytochalasin incubation was started 30 minutes after the blebbistatin plus 
cytochalasin mix to perform all of the test within the 4 hour time period.  
The actuator was set to move at a prescribed rate of 100 µm/s for 3 mm and then 400 
µm/s for 1 mm subsequent increments with approximately 30 s of relaxation between 
each increment until a set distance of 6 mm was reached. A mechanical dial indicator was 
attached to an adjustable mount to verify the distance traveled by the actuator and to 
corroborate the digitally displayed on the MP-285 actuator.  
4.2.2 Specimen Fabrication 
 
The dispensing of the blood was performed under a biological safety hood (SG303, 
The Baker Company, Sanford ME). 500 µL specimens were cast into a chamber slide 
with dimensions of 11 mm x 19.5 mm x 11.25 mm to obtain a consistent rectangular 
starting shape. The estimated starting size of all clots prior to retraction was 11 mm x 
19.5 mm x 2.3 mm. All blood clots were given 1.5 hours to retract and to stabilize in a 
relaxed state such that contraction forces would not interfere with results. The retraction 
of each specimen varied and thus required a microscope and a side camera to measure the 
specimen to calculate the actual dimensions, because inconsistent image analysis can 
adversely affect the results of the study [56].  
The whole blood control treatment consisted of 0.3 U of thrombin (Thermo Fisher 
Scientific, Waltham, MA) to initiate the clot, 10 µM of calcium chloride (Thermo Fisher 
Scientific, Waltham, MA) to replace the calcium initially removed during blood draw, 
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and 600 µL of blood to mix everything together. After mixing the clot three times 
(moving the fluid up and down) in the pipette for 5 s, 500 µL of the blood mixture was 
dispensed into the specimen well and the clot was allowed to retract and stabilize for 1.5 
hours in the biological safety hood.  
The other three treatments blebbistatin (Thermo Fisher Scientific, Waltham, MA), 
blebbistatin plus cytochalasin mix, and cytochalasin (Thermo Fisher Scientific, Waltham, 
MA) were incubated at room temperature (23 °C) for 30 minutes on a lab rocker (Vari-
Mix Platform Rocker, Thermo Fisher Scientific, Waltham, MA) at approximately 2 Hz 
with eppendorf tube secured horizontally to improve mixing with the whole blood. Table 
1 shows the concentrations used for the experiment. The blebbistatin and cytochalasin 
concentration values were higher than in other reported studies [35] to prevent 
contraction of the clot, by completely inhibiting the desired mechanism. The blebbistatin 
treatment had 300 µM of blebbistatin mixed with 600 µL of blood, the cytochalasin 
treatment had 10 µM of cytochalasin mixed with 600 µL of blood, and the combined 
blebbistatin plus cytochalasin had 300 µM of blebbistatin, 10 µM cytochalasin, and 600 
µL of blood. All three treatments had 0.3 U of thrombin and 20 µM of calcium added 
after the incubation period and were mixed within approximately 5 s in a pipette three 
times prior to dispensing 500 µL of the treated blood into the specimen wells. All 
specimens were left in the biological safety hood for 1.5 hours to complete retraction.  
 
 
 
29 
 
Table 1. Composition and timing used for each specimen type 
 
 
4.2.3 Apparatus and Measurement System 
 
The nanopositioner started at its left-most position to utilize the entire travel of the 
motor. The clamps were placed on the actuator and the load cell mount. The load cell and 
its corresponding clamp were attached on a micromanipulator (Cascade Microtech, 
Beaverton, OR), initially set flush with the opposing clamp on the actuator. Another 
micromanipulator with a dial indicator was set to zero prior on the load cell 
micromanipulator. The load cell clamp was then moved away from the actuator clamp 
until 4.24 mm on the dial indicator is read for total of 6 mm initial working distance (each 
clamp has a channel width of 0.88 mm). The dial indicator was moved perpendicular to 
the actuator and zeroed to verify the distances the actuator moved.  
The test data were extracted in terms of force and converted to the respective true 
stress vs. stretch ratio curves and stress relaxation curves. A specimen was continuously 
pulled to 3 mm at 100 µm/s which was 50% of the initial 6 mm working length to obtain 
the true stress vs. stretch ratio data. The specimen was allowed to rest for 30 s between 
each increment. All subsequent increments added additional 1 mm extend-and-hold 
operations, moving at 400 µm/s. At the end of the test, a total specimen length of 12 mm 
was reached at 100% specimen elongation. 
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The load cell was zeroed without the bottom support to neglect the weight of the 
specimen in the initial pull. Prior to pulling, the microscope was set to capture top-view 
images of the specimen to extract top cross-sectional dimensions, and the side camera 
was used to side-view images to extract thickness. The microscope captured three images 
during the pull, each 8 s apart. The force recording from the data acquisition software 
(LoadVUE, Loadstar Sensors, Fremont, CA) and actuation of the nanopositioner were 
started simultaneously and force measurements were recorded at 30 Hz. The actuator was 
controlled by legacy software "mp285.exe" provided by the nanopositioner manufacturer 
(Sutter Instrument Company, Novato, CA), and followed the sequence stated earlier. As 
soon as the first actuation stage completed, the second specimen side view picture was 
taken prior to the 30 second timer starting for the stress relaxation pulls. The pull timing 
allowed for 3 s of travel. After, every 30 s the next actuation stage was enabled. The 
times were 30 s, 1 minute 3 s, 1 minute 36 s, 2 minutes 9 s, and 2 minutes 42 s. The entire 
pull portion of the experiment took 3 minutes 12 s to complete. 
4.2.4 Image Analysis 
 
The image analysis tool Fiji was used to measure the three top-view images for the 
width w and two side images for thickness t [57]. Figure 8 show a typical set of images 
that were captured during the true stress vs. stretch ratio portion of the experiment from 
the top view. Each image was used to understand the changing cross-section of the 
specimen. The 12.7 mm clamp width was a reference feature used to measure the clot 
width at the center of the specimen in each image. A fitted line from each of the three 
images was used to estimate the change in width and thereby to determine the cross-
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sectional area of the specimen. Force measured by the load cell was divided by cross-
sectional area to calculate true stress. 
 
Figure 8. Standard top down three images at 8 s apart for each specimen.  
 
Figure 9 shows the two images taken on the side to measure the change in thickness 
over time for the true stress vs. stretch ratio portion of the experiment. The 3 mm clamp 
thickness was used as a reference feature to calculate the for clot thickness at the center 
of the specimen. A straight line drawn across the center was used to measure the 
specimen thickness change. The specimen cross-section was not quite rectangular, but 
closer to an elliptical profile with rounded edges. Equation 12 used the width and 
thickness founded to calculate the true stress with the changing area as an ellipse.  
 
(12) 
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Figure 9. Side view of specimen being pulled from initial (left) to 3 mm extension (right). 
 
4.2.5 Data Analysis 
 
Figure 10 shows a representative example of raw data plot from the test. The first 
portion of data was used to plot true stress vs. stretch ratio. The first stress relaxation 
curve (in the 30 s to 60 s time frame) following the initial pull was discarded so that each 
step change for stress relaxation could be applied in a consistent manner. The next three 
pulls was used for the stress relaxation portion of the study.  
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Figure 10. Representative extension curve to extract true stress vs. stretch ratio plots and 
stress relaxation plots. 
 
The force for the strain stiffening portion of the test reached a maximum of 3.5 g 
which was a factor of 10 less than the load cell operating range of up to 113 g. Force was 
divided by the changing area to provide the true stress of the specimen. The time output 
was converted to a stretch ratio with the known displacement rate and initial specimen 
length. Mooney-Rivlin fit parameters can be extracted from the plots. 
The first three seconds of each relaxation curve was analyzed by fitting the 
experimental data to equation 11. Figure 11 shows a sample plot of the three pull 
distances overlaid with the fitted equation 11 used to extract parameters k1, k2, and  . The 
important parameter k1 and       P D N H  X S  W K H  W L P H  F R Q V W D Q W 2       N 1, because k2 only shifts 
the height of the plot and does not play a role in how fast the curve decreases. 
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Figure 11. A consolidated fitted curve plot at the 4 mm, 5 mm, and 6 mm on the first 3 s 
of the specimen pulls. 
 
To determine donor-to-donor variability the Mooney-Rivlin parameters was used in a 
one way analysis of variance (ANOVA) at a 99% confidence interval (.  = .01) based on 
whole blood specimens only. C1 and C2 each had an independent ANOVA performed, 
because the values are dependent on each other. Each parameter will need to have a high 
p-value for all the donors to be equal. The differences between the maximum and 
minimum C1 and C2 values within each donor provides the within donor variability 
information.  
4.3 Sources of Uncertainty 
In the test calibration, a 10.950 g weight displayed an average force output of 108.54 
mN resulting in a 1.05% error from the theoretical force 107.42 mN, the 20.95 g weight 
displayed an average force output of 207.29 mN resulting in 0.86% error from the 
theoretical force 205.52 mN, and 51.250 g weight measured 508.16 mN, resulting in a 
1.07% error from the theoretical force 502.76 mN. The scale used to measure the weights 
had a resolution of 0.1 mg. 
Actuator speeds were verified against the program values. The speed was checked 
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against the distance. A 12.7 mm depth gauge was attached on the actuator to verify 
distance traveled for the two prescribed rates of 20 µm/s and 60 µm/s. The actuator was 
programmed to move 2.54 mm at the rates of 20 µm/s and 60 µm/s, and a stopwatch 
verified the times to be 127 s and 42.3 s, respectfully. The dial has a resolution of 25.4 
µm and the estimated average human reaction time is roughly 0.25 s. 
The stiffness of the load cell calculation will vary on many parameters, because all of 
the measurements will affect the length and cross-sectional values used to determine the 
stiffness value. The length, width, and thickness were measured with a micrometer with a 
resolution of 2.5 µm. The load cell deflection was measured on an optical comparator by 
putting the load cell flat lengthwise to allow for known weights to be added at the end. A 
zero reference was created with the unloaded load cell. Weights were added the static 
system and then measured by a comparator with an uncertainty of ± 2.5 µm. In the image 
analysis there was a pixel uncertainty of approximately ± 10 µm. Table 2 is a 
summarized list of uncertainties that was used to calculate apparatus uncertainties in true 
stress reporting and load cell stiffness. 
Table 2. List of uncertainties 
 
 
Using the list of uncertainties in Table 2, the apparatus measurement uncertainty was 
calculated. Applying equation 13, the propagation of uncertainty, a square root sum of 
squares of uncertainties, is used to estimate the total uncertainty. A combined error u, is 
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characterized by f which is the function with the unknown uncertainty with the sources of 
error. The first source of uncertainty is 𝑦1with an uncertainty range defined as 𝑢1.  
 
(13) 
 
To find the cross-sectional area uncertainty from the image analysis equation 14 is used. 
The two sources of uncertainty are thickness and width which are both from image 
analysis tool. All specimens have different cross-sections and a smaller cross-section 
would result in a larger stress uncertainty in later calculations. The assumed dimensions 
are 0.85 mm thick x 7.74 mm wide, because those were the smallest measured values for 
each of their respective features. The combined uncertainties resulted in a cross-sectional 
uncertainty of 0.06 mm² with the image analysis tool. 
 
(14) 
 
With the result from equation 14, the reported stress uncertainty is calculated with 
equation 15. By using the load cell uncertainty from Table 2 and the previous area 
uncertainty an overall stress uncertainty was calculated. The upper range specimen force 
of 34.3 mN and lower range specimen area of 5.18 mm² is used to calculate a stress 
uncertainty of 102.63 Pa or 1.55% error for the nonlinear stiffness calculations. 
 
(15) 
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For equation 16, the load cell stiffness uncertainty, an assumed force of 106.4 mN from 
the calibration measurement and a deflection of 1.24 mm. An uncertainty of 0.17 N/m 
was found for the load cell stiffness. 
 
(16) 
 
The apparatus loading style is subjected to sine error due to the vertical orientation of 
the load cell and the horizontal pulling of the specimen in relation to the load cell. 
 ( T X D W L R Q     L V  X V H G  W R  F D O F X O D W H  W K H  V L Q H  H U U R U 0   7 K H  F O D P S  G L V W D Q F H  K  I U R P  W Ke load cell 
is 24 mm to the specimen contact and the angle   was calculated from force deflection 
with the load cell stiffness. The maximum forces used are 34.3 mN for the nonlinear 
stiffness and 106.4 mN for the stress relaxation resulting in an error of 0.42 mm and 1.30 
mm respectively. 
 
(17) 
 
However, with image analysis, the clamp shift was found to be closer to 0.12 mm at the 
34.3 mN pull. The loading of the cantilever was not exactly the same as the specimen 
being pulled on the clamps, because the mounting adapter could not attach to the weights 
used for calibration.  
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5. RESULTS AND DISCUSSION 
There are two main types of results from a single pull sequence. The first result is 
how the inhibitor treatments affect the stiffness of the specimen, as revealed in a plot of 
true stress vs. stretch ratio. The second result is how the inhibitor treatments affect the 
stress relaxation of the specimen.  
5.1 Effective Nonlinear Stiffness of Blood 
Figure 12 shows fitted two-parameter Mooney-Rivlin curves for true stress vs. stretch 
ratio for each of the treatments, averaged across all donors and specimens. The plot 
shows that whole blood has the highest stiffness of all the treatments, as expected 
because the structure has not been altered with any inhibitors. Based off of the maximum 
true stress found on the plot in Figure 12, cytochalasin decreased clot stiffness by 33.7% 
and blebbistatin decreased clot stiffness by 37.9%. The blebbistatin plus cytochalasin mix 
decreased the clot stiffness by 44.8%. The difference between blebbistatin and 
cytochalasin is 4.3%, and is greater than the 1.55% uncertainty in true stress, as estimated 
in Section 4.3. 
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Figure 12. Fitted Mooney-Rivlin hyperelastic model on the averaged treatment results 
across all donors. 
 
 The true stress vs. stretch ratio showed that the whole blood clot was structurally 
stiffer than the inhibitor-treated clots. Blebbistatin has a lower true stress at maximum 
stretch ratio than cytochalasin by 4.3%. Although based on limited sample size and fixed 
concentration, this offers some supports to the hypothesis that blebbistatin affects the 
blood structure to a greater extent, by preventing the cross-linking of actin filaments 
through the inhibition of myosin II, thus reducing the overall clot contraction strength. 
Cytochalasin affects the actin filament length by preventing actin from depolymerization 
and repolymerization, shortening the myosin II travel distance on the actin. However, the 
capped actin filaments did not inhibit the myosin II function, causing the cytochalasin 
treatments to yield stiffer clots. Blebbistatin prevented myosin II function, which created 
a gap between the actin proteins, because there were no protein cross-linkage 
interactions. The larger distances between proteins during the pull testing, resulted in a 
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weaker clot structure, because there was empty space that could easily collapse. The 
blebbistatin plus cytochalasin combination affected two different mechanisms, which are 
the myosin II travel on actin filaments and the actin filament polymerization length. The 
combination of both inhibitors resulted in clots with the lowest overall stiffness. 
5.2 Viscoelastic Response of Blood 
 
The bar graph in Figure 13 shows how the time constant 2 differs for the four 
 G L I I H U H Q W  W \ S H V  R I  E O R R G  F O R W V   $  V P D O O H U  Y D O X H  R I 2  P H D Q V  U D S L G  G H F D \  D Q G  L P S O L H V  U H O D W L Y H 
inability to sustain tensile stress. As seen in Figure 13, the fastest 2 was observed for the 
blebbistatin treatment, and whole blood had the slowest time constant at 4 mm extension. 
At 5 mm extension, the blebbistatin treatment also exhibited the fastest time constant but 
the cytochalasin treatment showed slower response than whole blood. At 6 mm, the 
inhibitor mix blebbistatin plus cytochalasin was faster than blebbistatin and cytochalasin 
was the slowest. The overall data across the three distances imply that blebbistatin, with 
the fastest time constant, weakens the clot more than cytochalasin. The cytochalasin 
specimen decay time became slower than whole blood at larger pull distances, which was 
unexpected. 
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 ) L J X U H      7 L P H  F R Q V W D Q W 2  Y D O X H V  I R U  H D F K  W U H D W P H Q W  D W    P P     P P   D Q G    P P  
 
 All of the treatments have a similar unexpected trend with slower time constants at 5 
mm, but a slightly faster time constant at 6 mm as seen in Table 3. At larger distances, 
environmental factors such as prolonged air exposure can dry-out the clot and alter the 
results. Thus, behavior at 6 mm extension is less revealing about changes in clot 
structure. The time constants at 4 mm extension are considered more accurate, since there 
are fewer uncontrollable variables in the first pull than in the later pulls. The faster time 
constants from the stress relaxation exhibit the treatment effects. Blebbistatin has a 10.2% 
faster time constant than whole blood. The cytochalasin specimen did not differ from 
whole blood greatly by only being 0.0317% lower.  
Table 3. Time constant differences between inhibitor treatments and the whole blood 
control at each extension distance 
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5.3 Donor Variability  
5.3.1 Within-Donor Variability 
The variability within donors is shown in Figure 14. Figures 14-1 and 14-2 show 
specimens in black that are initially weaker than the rest, but see strain stiffening, causing 
the specimen to reach a higher end stress. The increased strain stiffening resulted in 
specimen curve in black to intersecting with other specimen curves. Figures 14-2, 14-3, 
and 14-4 all have a within donor maximum stress difference of 2 kPa at the 1.45 stretch 
ratio. 
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Figure 14. Plots of whole blood donor replicate variability for five donors where each 
curve is a separate test specimen. 
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The ranges of fitted Mooney-Rivlin parameters C1 and C2 are presented in Table 4, 
arranged by donor. Donor 2 had the highest variability among the specimens in terms of 
plot shape, as shown in Figure 14-2, with the largest overall calculated variation of 58% 
for C1 and of 62% for C2. The larger C2 range compared to the C1 range correlated with 
curves intersecting. Each parameter affects the curve, such that C1 values change the true 
stress maximum height and C2 values change the plot curvature shape. Donor 1, 3, and 4 
had comparable ranges, but Donor 5 had the smallest difference between values.  
Table 4. Whole blood Mooney-Rivlin hyperelastic parameters C1 and C2 range for each 
donor  
 
 
5.3.2 Donor-to-Donor Variability 
 
The variability of all treatments across donors was unpredictable with no obvious 
trend as seen in Figure 15. The whole blood with no treatment across all donors had the 
highest variability. In Donor 5 the whole blood specimen with highest observed stiffness 
had maximum true stress that was approximately twice the true stress of the next highest 
whole blood specimen. The effects of all other treatments were difficult to determine, 
because they varied between donors. In Donor 1, blebbistatin and cytochalasin are shown 
with comparable stiffnesses. In Donor 2, cytochalasin appeared to have no effect on the 
blood. In Donor 3, the results are similar to the averaged Mooney-Rivlin results with 
whole blood as the stiffest specimen and blebbistatin weaker than cytochalasin. In Donor 
4, blebbistatin is the weakest, but in Donor 5 blebbistatin is unexpectedly higher than 
cytochalasin.  
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Figure 15. Plots of true stress vs. stretch ratio averaged across five donors per treatment 
response by each donor. 
 
Analysis of variance (ANOVA) was used to check for statistically significant 
differences among donors, with each of the two Mooney-Rivlin parameters as separate 
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response variables, and donor number as the factor of interest. The control whole blood 
was chosen to determine if there were any difference between the donors and to avoid 
inhibitor effects on specific donors. Table 5 shows that the C1 value for five donors had 
weak evidence of any differences with a p-value of 0.60. Donor 2 showed the highest 
variance and donor 5 had the lowest variance, similar to the within donor range shown in 
Figure 14.  
Table 5. Mooney-Rivlin parameter C1 one way ANOVA comparison across donors for 
whole blood 
 
 
In Table 6, C2 has a p-value of 0.71, showing weak evidence that the donors are 
unequal. The high p-value indicates that all the curvatures were similar. Donor 2 showed 
the highest variance and Donor 5 had the lowest variance which was also shown in 
Figure 14 whole blood donor plots. 
 
 
 
 
47 
 
 
Table 6. Mooney-Rivlin parameter C2 one way ANOVA comparison across donors for 
whole blood 
 
 
The ANOVA of the Mooney-Rivlin parameters showed no statistically significant 
differences with respect to donor for whole blood specimens. Thus the averages from 
each donor are used for comparing each of inhibitor treatments, even though the 
composition of specimens from each donor may have had a different platelet and red 
blood cell count. 
The average maximum stress between donors for all treatments for a stretch ratio of 
1.45 is shown in Table 7. Whole blood was used as the reference and for each donor there 
was a shift in the effectiveness of blebbistatin and cytochalasin observed in the plots. In 
Table 7, whole blood, blebbistatin, and cytochalasin had a donor maximum stress range 
of 2.23 kPa, 0.29 kPa, and 1.26 kPa respectively. The percentage difference from whole 
blood ranged from 24.5% to 55.4% for blebbistatin and 6.81% to 69.8% for cytochalasin. 
The donor-to-donor variability for drug effectiveness had a large range in percentage 
change.  
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Table 7. Average maximum stress value percent difference at 1.45 stretch ratio for each 
treatment with whole blood as the reference 
 
The time constants also varied from donor-to-donor shown in Table 8. For all donors 
except Donor 3, the treatment time constants at 4 mm were slower than whole blood time 
constant. In all donors, at 4 mm, the blebbistatin treatment time constants were faster than 
the cytochalasin treatment time constants. Whole blood, blebbistatin, and cytochalasin 
had a time constant range between donors of 0.22 s, 0.25 s, and 0.21 s respectively. The 
time constant ranges varied by no more than 24% within any given treatment type. 
 7 D E O H     $ Y H U D J H 2  Y D O X H  S H U F H Q W  G L I I H U H Q F H  D W    P P  Z L W K  Z K R O H  E O R R G  D V  W K H 
reference 
 
5.3.3 Other Sources of Uncertainty 
 
Within the specimen fabrication, there were small air bubbles (on the order of 100 µm 
in diameter) on the specimen when being pulled as seen in Figure 16. The bubbles would 
sometimes appear over time during the test, even though bubbles were not visible in the 
original specimens prior to testing. The largest bubbles typically measure approximately 
0.3 mm in diameter. Overall, the bubbles are sparse and a single clot may have as many 
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as 10 on the surface of the clot ranging from 0.18 mm to 0.30 mm in diameter. None of 
the bubbles ruptured or created tears in the clot. 
 
Figure 16. Top view image of bubbles present in the clot pull. 
 
Figure 17 shows that the clot spills over the clamp when being secured in the 
apparatus. Small force components can be attributed to the blood surface tension with the 
clamp as a wetted meniscus. All of the clots behaved this way with plasma leaking out of 
the sides, but it is difficult to quantify the adhesion affected clot strength. The current 
assumption is that the plasma adhesion force is the same for all specimen tests. The test 
was not performed under controlled temperature or humidity, and the lack of controlled 
environment may have allowed the clot to dry and shrink over time. 
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Figure 17. Side image of blood adhering to the clamp creating a wetted meniscus. 
 
The extent and uniformity of mixing are difficult to verify, because different volumes 
were used to obtain the desired treatment concentration. The assumption is that all 
samples are evenly mixed, meaning the thrombin, calcium chloride, and inhibitors were 
equal throughout the clot. There is a possibility that nonuniform mixing for blebbistatin 
was more pronounced, because the blebbistatin clot uses a larger volume of 53 µL to mix 
for a final concentration of 300 µM, whereas cytochalasin uses a volume 12 µL to mix 
for a final concentration of 10 µM. 
The 300 µM blebbistatin and 10 µM cytochalasin are assumed to inhibit all myosin II 
and actin respectively. Since there is only one dosage performed for each treatment, the 
effects are possibly dose dependent [29], [58]. There is an uncertainty if the dosages were 
used at a toxic level and potentially causing adverse effects on the blood clot. From 
similar literature, Tutwiler et al. used 200 µM blebbistatin in their studies of clot 
contraction [9]. Ayala et al. used 5 µM of cytochalasin D and 10 µM of blebbistatin and 
found that in rheometry the results were the opposite, by showing that cytochalasin 
affected the clot more with only 5 µM concentration [29]. However, Crow et al. used 500 
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nM of cytochalasin and 30 µM blebbistatin to conclude that blebbistatin affected the clot 
contraction more at those concentrations [35]. In this same research by Crow, 1 µM 
cytochalasin and 50 µM blebbistatin concentrations were found to inhibit all contraction 
in the clot. 
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6. CONCLUSIONS 
6.1 Addressing the Hypothesis 
 
The hypothesis asserted that blebbistatin affects the stiffness and viscoelastic 
response of blood clots more than cytochalasin D, because myosin II plays a larger role 
than actin in affecting the mechanical strength of the clot. The variability of nonlinear 
stiffness for each individual donor was substantial, for example the C1 parameter which 
affects the maximum true stress, had a variation as large as 61% for whole blood. 
However, the nonlinear stiffness in terms of true stress vs. stretch ratio averaged across 
five donors showed that blebbistatin affected the clot maximum true stress at 1.5 stretch 
ratio by 4.3% more than cytochalasin. The 4.3% difference is greater than the calculated 
1.6% uncertainty associated with quantifying true stress. From the averaged viscoelastic 
parameters at each increment of elongation, blebbistatin decayed more rapidly than 
cytochalasin, with a 10% shorter time constant at 4 mm elongation. Both the nonlinear 
stiffness and stress relaxation revealed similar results, which were consistent with 
biophysical reasoning that the myosin II inhibition prevents the cross-linking of the actin 
and myosin travel on actin, thus influencing structural behavior to a greater extent than 
cytochalasin.  
Differences between the inhibitor-treated specimens were detectable with a tensile 
testing methodology. There was no statistically significant difference ( .  = 0.01) found 
across five different donors. The time constant for cytochalasin was slower than the time 
constant for whole blood by 3.5% at 5 mm and 6.9% at 6 mm.  
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6.2 Recommendations for Future Work 
 
Based on this work, a climate controlled environment is recommended to minimize 
possible environmental effects on the specimen during testing. A different actuator can be 
used, because the apparatus only needs a few millimeters of travel. Greater consistency 
can be achieved by using a programmable actuator that could pull and allow for 30 s of 
stress relaxation, instead of manually timing the pull start and stop sequence. An 
integrated system to activate the actuator, initiate data acquisition, take the side-view 
images, and the top view images could reduce possible errors introduced by operator. The 
clamps can be improved by developing a way to achieve constant prescribed force 
(magnetic or otherwise). A shorter initial working length will prevent unwanted specimen 
sag on clamps to start at a proper length for more consistent results. In the stress 
relaxation analysis, the viscoelastic model in this thesis uses force over time, which does 
not account for overly large clots to cause a slower stress relaxation time constant. A 
stress over time standard linear model may provide different results, because the area can 
be normalize to provide a more precise comparison between treatments [59]. The tensile 
testing approach with clamps allows for a more in depth understanding of clots and other 
soft biological materials in the micromechanical scale. 
A minimum threshold is needed to understand when the drugs will interact with the 
clot. The established threshold will allow for a controlled change in parameters to avoid 
studying unwanted treatment effects not related to the desired mechanism. After 
minimum drug concentrations have been established, a two factor, three level factorial 
design of experiments can be conducted. The three levels would be low, medium, and 
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high doses of each treatment to check for the required threshold to inhibit all activity or 
extrema, and to also reveal possibly nonlinear interactions. 
A different approach to supplement the testing is to use Western blotting [60] to 
corroborate and verify the effects of both drugs. The test can have the same four 
treatments of whole blood, blebbistatin, cytochalasin D, and the blebbistatin plus 
cytochalasin. The protein markers can be made to view the myosin II and the actin II for 
each treatment and compare gels for each treatment. If the gel is more pronounced then 
there is an indication of a higher concentration. A visual representation can be obtained 
by staining the platelets to highlight the actin and myosin II proteins. 
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APPENDIX A:  APPARATUS TECHNICAL DOCUMENTS 
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APPENDIX B:  GLOSSARY 
 
Alginate - An extract from brown seaweed cell walls that can be mixed with calcium and 
sodium salts to create a flexible fibre. 
 
Actin - A thin protein in the cytoskeleton that interacts with myosin II in a primitive 
sarcomere like.  
Aneurysm - A localized region in a blood vessel that is abnormally large due to 
thrombosis or embolization which is a piece of material inside the blood vessel causing 
blockage. 
Blebbistatin - A myosin inhibitor for myosin II which would prevent ATP, resulting in a 
low energy state. 
Coagulation - The process of blood changing from a liquid to a solid with the activation 
of platelets and fibrin to form a clot. Thrombosis or hemorrhaging can occur due to 
coagulation clotting issues. 
Collagen - A main structural protein that can be found throughout the body. 
Clot - Solidified blood. 
Cytochalasin - A fungal mobilite that can block and inhibit polymerization and 
elongation of actin. 
Cytochalasin D - Inhibits actin polymerization by capping the ends of the actin chain. 
Denaturation - A process where proteins can lose structure, typically caused by the 
environment such as heat or a chemical reaction. 
Eptifibatide - An antiplatelet drug that prevents blood from clotting and be used for heart 
attacks in people with severe chest pains. 
Factor XIII (FXIII) - Also known as fibrin stabilizing factor, is an enzyme that will 
cross-link fibrin. 
Fibrin - A fibrous protein formed from thrombin and fibrinogen. The protein can be 
polymerized with platelets to form a clot over a wound. 
Fibrinogen - Also known as factor I and when combined with thrombin it forms a fibrin 
based blood clot. 
Fibrinolysis - Prevents blood clots from growing too large and becoming problematic. 
The fibrin clot is broken down and the remains are cleared by proteases or by organs like 
the kidney or liver. 
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Fibroblasts - Synthesizes extracellular matrix and collagen, which is critical to wound 
healing. 
FFP (Fresh Frozen Plasma) - Liquid portion of whole blood that can be used to treat 
conditions with low blood clotting factors. 
Hemarthrosis - Bleeding in the joints due to lack of factor XIII. 
Hemophilia - The ability to have blood clot is severely reduced relative to normal 
population due to missing clotting factors. 
Hemostatic- An antihemorrhagic agent that contracts tissue to seal wounds. 
Hydrogel - A gel with water as the main liquid, can be used in biological functions to 
help with wound healing.  
Ischemic - Restricted blood flow to regions causing a lack of oxygen needed for basic 
cellular metabolism. 
Lysis - Breaking down.  
Myocardial infarction - Another term for heart attack which happens when there is 
restricted blood flow to the heart, causing damage to the heart. 
Myosin II - A protein that assists in providing cellular structure by binding and traveling 
along actin filaments. 
Plasma -  & R Q W U L E X W H V  W R      R I  W K H  E R G \ ¶ V  W R W D O  E O R R G  Y R O X P H  Z K L F K  F R Q W D L Q V  G L V V R O Y H G 
proteins such as fibrinogen. Also contains proteins, ions, nutrients, and waste. 
Platelet - Also known as thrombocytes and is a component of blood that can clump and 
clot blood. 
PRP (Platelet Rich Plasma) - A concentration from whole blood. Platelet-rich plasma is 
centrifuged to remove red blood cells. Has a greater concentration of cellular growth 
factors (e.g. PDGF, IGF-1, EGF, and TGF-beta) activating fibroblasts.  
PPP (Platelet Poor Plasma) - Blood plasma with a low number of platelets that can have 
an elevated level of fibrinogen. 
Stroke - Restricted blood flow due to ischemia or hemorrhage where there is bleeding in 
the skull. 
Thrombin - Acts as a serine protease that converts soluble fibrinogen into insoluble 
strands of fibrin. 
Thrombosis - Formation of a blood clot in a blood vessel with platelets and fibrin. 
Thrombolysis - Breakdown of a blood clot in a blood vessel. 
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APPENDIX C:  EXPERIMENTAL PLOTS 
 
 
Mooney-Rivlin %
5and %6parameters in dot 
plot form 
Extracted viscoelastic G
6 spring parameter 
at 3 second 
 
 
Extracted viscoelastic G
5 spring parameter 
at 3 s 
Extracted viscoelastic   spring parameter at 
3 s 
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Extracted viscoelastic G
5 spring parameter 
at 30 s 
Extracted viscoelastic G
6 spring parameter 
at 30 s  
 
 
Extracted viscoelastic   spring parameter at 
30 s 
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APPENDIX D:  RAW EXPERIMENTAL IMAGES 
 
 
 
Donor 1 whole blood top view images Donor 1 blebbistatin top-view images 
  
Donor 1 cytochalasin top-view images Donor 1 blebbistatin plus cytochalasin 
mixture top-view images 
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Donor 2 whole blood top-view images Donor 2 blebbistatin top-view images 
  
Donor 2 cytochalasin top-view images Donor 2 blebbistatin plus cytochalasin 
mixture top-view images 
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Donor 3 whole blood top-view images Donor 3 blebbistatin top-view images 
  
Donor 3 cytochalasin top-view images Donor 3 blebbistatin plus cytochalasin 
mixture top-view images 
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Donor 4 whole blood top-view images Donor 4 blebbistatin top-view images 
 
 
Donor 4 cytochalasin top-view images Donor 4 blebbistatin plus cytochalasin 
mixture top-view images 
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Donor 5 whole blood top-view images Donor 5 blebbistatin top-view images 
 
 
Donor 5 cytochalasin top-view images Donor 5 blebbistatin plus cytochalasin 
mixture top-view images 
 
 
 
 
  
73 
 
 
  
Donor 1 whole blood side-view images Donor 1 blebbistatin side-view images 
  
Donor 1 cytochalasin side-view images Donor 1 blebbistatin plus cytochalasin 
mixture side-view images 
  
Donor 2 whole blood side-view images Donor 2 blebbistatin side-view images 
  
Donor 2 cytochalasin side-view images Donor 2 blebbistatin plus cytochalasin 
mixture side-view images 
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Donor 3 whole blood side-view images Donor 3 blebbistatin side-view images 
  
Donor 3 cytochalasin side-view images Donor 3 blebbistatin plus cytochalasin 
mixture side-view images 
 
 
Donor 4 whole blood side-view images Donor 4 blebbistatin side-view images 
 
 
Donor 4 cytochalasin side-view images Donor 4 blebbistatin plus cytochalasin 
mixture side-view images 
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Donor 5 whole blood side-view images Donor 5 blebbistatin side-view images 
  
Donor 5 cytochalasin side-view images Donor 5 blebbistatin plus cytochalasin 
mixture side-view images 
  
